FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

A / la :	D 0	205 40
Washington,	D.C.	20549

STATEMENT	OF	CHANGES	IN	BENEFIC	CIAL	OWNE	RSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>LANGER ROBERT</u>					2. Issuer Name and Ticker or Trading Symbol Frequency Therapeutics, Inc. [FREQ]							ck all applica Director	10% Owi		mer	
	QUENCY	irst) THERAPEUTIO SUITE 300	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 08/17/2022							Officer (below)	give title		Other (s below)	pecify
(Street) LEXING	TON M	IA tate)	02421 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)					Line)	Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(2.9)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3) 2. Tr			2. Transac Date (Month/Da	action 2A. Deemed Execution Date,		3. Transaction Code (Instr. 2)			(A) or	or 5. Amount of Securities Beneficially Owned Follo		6. Own Form: (D) or I (I) (Inst	Direct I ndirect E r. 4) (7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code V	Amount	(A) or (D) Price		Reported Transaction(s) (Instr. 3 and 4)						
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year) 3. Deemed Execution E if any (Month/Day		te, Tran	4. Transaction Code (Instr.		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		I Amount es J Security d 4)	8. Price of Derivative Security (Instr. 5)			10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Cod	e V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Stock Option	\$2.14	08/17/2022		A		14,846		(1)	06/10/2030	Common Stock	14,846	(2)	14,846	5	D	
Stock Option	\$18.63	08/17/2022		D			14,846	(3)	06/10/2030	Common Stock	14,846	(2)	0		D	
Stock Option	\$2.14	08/17/2022		A		14,846		(4)	06/16/2031	Common Stock	14,846	(2)	14,846		D	
Stock Option	\$10.14	08/17/2022		D			14,846	(5)	06/16/2031	Common Stock	14,846	(2)	0		D	

Explanation of Responses:

- 1. The option vested in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders.
- 2. The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.
- 3. The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders.
- 4. The option vested in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.
- 5. The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.

/s/ James P. Abely, Attorney-in-08/19/2022 Fact for Robert S. Langer

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.